comparemela.com

Latest Breaking News On - Iodexa pharmaceuticals kurs - Page 1 : comparemela.com

Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)

26.04.2024 - April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in . Seite 1

Emtora biosciencesBiodexa pharmaceuticalsNational cancer instituteResearch institute of texasRapamycin holdings incNational institutes of healthPivotal phaseCancer preventionResearch instituteNon muscle invasive bladder cancerNational institutesRapamycin holdingsBiodexa pharmaceuticals chartIodexa pharmaceuticals kursIodexa pharmaceuticals aktie

Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology Meeting (EANO)

21.09.2023 - Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa to Present Recruitment and Treatment Update in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma at 2023 Annual European Association of Neuro-Oncology . Seite 1

Dmitry zamoryakhinBiodexa pharmaceuticals chartIodexa pharmaceuticals kursIodexa pharmaceuticals aktie

vimarsana © 2020. All Rights Reserved.